Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274599 · ClinicalTrials.gov registry record · Phase 4
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 812
- Enrollment target
NCT00274599 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 812 participants.
The verdict
NCT00274599, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 812 participants
- Enrollment target
Study Summary
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
Interventions
- DRUG Ramipril
- DRUG Telmisartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 812 participants |
| Start Date | 2002-10-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274599
The ClinicalTrials.gov registry entry for NCT00274599 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 812 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ramipril is the first listed.
NCT00274599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274599 about?
NCT00274599 is a clinical study titled "PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN". Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
What is the current status of trial NCT00274599?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 812 participants. The study started on 2002-10-09.
What interventions are being tested in trial NCT00274599?
The interventions under investigation include: Ramipril (DRUG), Telmisartan (DRUG).
Who is sponsoring clinical trial NCT00274599?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.